Hansoh Pharmaceuticals, a China-based drug developer, has completed its initial public offering on the Hong Kong Stock Exchange, selling 551 million shares at HKD14.26 per share, generating gross proceeds of HKD7.9 billion (approximately USD1 billion). Existing private investors Boyu Capital and Hillhouse Capital retained their stakes of 3.29 percent and 2.91 percent, respectively, in the company and participated as cornerstone investors in the offering along with Singaporean sovereign wealth fund GIC, Ally Bridge Group, OrbiMed Advisors, and Vivo Capital among others.